GO:0009008 DNA-methyltransferase activity: Mechanism, Genes and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0009008 DNA-methyltransferase activity is defined as catalysis of methyl group transfer to a DNA molecule, a core epigenetic modification.
• DNA methylation is essential for gene regulation, genomic imprinting, X-chromosome inactivation, and genome stability, and its dysregulation is a hallmark of cancer and other diseases.
• The activity is mediated by DNA methyltransferases (DNMTs) that use S-adenosyl-L-methionine (SAM) as the methyl donor and flip the target base into the catalytic pocket.
• Numerous assays have been developed to measure DNA-methyltransferase activity, including radioactive, fluorescence, electrochemical, and CRISPR-based methods [1,2,3,4,6,7,8].
• Aberrant DNA methylation patterns are implicated in cancer, imprinting disorders, and neurological diseases, making DNMTs important therapeutic targets.
• CRISPR-based models (knockout, point mutation, knock-in, overexpression) enable precise functional dissection of DNMT genes and their roles in disease [1,5].
Description
DNA-methyltransferase activity (GO:0009008) is a molecular function that catalyzes the transfer of a methyl group to a DNA molecule, typically at the carbon-5 position of cytosine within CpG dinucleotides. This epigenetic modification is fundamental to gene regulation, development, and genome stability, and its dysregulation is associated with cancer and other diseases. The activity is executed by a family of enzymes known as DNA methyltransferases (DNMTs), which utilize S-adenosyl-L-methionine (SAM) as the methyl donor. Understanding the mechanism, regulation, and biological roles of DNA-methyltransferase activity is crucial for researchers in epigenetics, cancer biology, and developmental biology. Moreover, accurate measurement of this activity is essential for drug discovery and diagnostics, driving the development of sensitive and high-throughput assays [1,2,3,4,6,7,8].
DNA-methyltransferase activity At A Glance
| GO ID | GO:0009008 |
|---|---|
| GO term | DNA-methyltransferase activity |
| Ontology | molecular_function |
| Synonym | DNA methylase, DNA methyltransferase activity, deoxyribonucleic acid methyltransferase activity, Type II DNA methylase |
| Major function | Catalysis of methyl group transfer to DNA, typically at cytosine bases, using SAM as cofactor |
| EC number | 2.1.1.37 |
| Cofactor | S-adenosyl-L-methionine (SAM) |
| Substrates | DNA (cytosine or adenine bases), SAM |
| Products | Methylated DNA (e.g., 5-methylcytosine), S-adenosyl-L-homocysteine (SAH) |
What Is GO:0009008?
DNA-methyltransferase activity (GO:0009008) is defined as the catalysis of the transfer of a methyl group to a DNA molecule. This enzymatic activity typically modifies cytosine residues to form 5-methylcytosine, a key epigenetic mark that influences chromatin structure and gene expression without altering the DNA sequence [1,5].
Why Is DNA-methyltransferase activity Important in Cell Biology?
DNA-methyltransferase activity is central to epigenetic regulation, influencing gene expression, development, and disease. It establishes and maintains DNA methylation patterns that are critical for genomic imprinting, X-chromosome inactivation, and silencing of repetitive elements. Dysregulated DNA methylation is a hallmark of cancer, where hypermethylation of tumor suppressor promoters and global hypomethylation contribute to oncogenesis. Therefore, measuring and manipulating this activity is vital for understanding disease mechanisms and developing epigenetic therapies.
• Regulates gene expression by adding methyl groups to DNA, often leading to transcriptional repression.
• Essential for embryonic development, genomic imprinting, and X-chromosome inactivation.
• Maintains genome stability by silencing transposable elements and repetitive sequences.
• Its dysregulation is implicated in cancer, where aberrant methylation patterns drive tumorigenesis.
• Plays a role in neurological disorders and aging through epigenetic changes.
• Serves as a target for epigenetic drugs (e.g., DNMT inhibitors) in cancer therapy.
• Accurate measurement of activity is crucial for drug discovery and clinical diagnostics [1,2,3,4,6,7,8].
• Enables researchers to study epigenetic inheritance and cellular reprogramming.
• Provides a basis for understanding environmental influences on the epigenome.
• Facilitates the development of biosensors and diagnostic tools for methylation-related diseases [4,7].
Molecular Mechanism of DNA-methyltransferase activity
Substrate Recognition and Base Flipping
In simple terms: The enzyme finds the target DNA base and flips it out of the double helix to modify it.
DNA methyltransferases recognize specific DNA sequences, typically CpG dinucleotides, and flip the target cytosine out of the DNA helix into the catalytic pocket. This base-flipping mechanism is essential for accessing the C5 position of cytosine for methyl transfer.
Methyl Group Transfer from SAM
In simple terms: The enzyme takes a methyl group from SAM and attaches it to the DNA base.
The methyl group is transferred from the cofactor S-adenosyl-L-methionine (SAM) to the flipped cytosine, forming 5-methylcytosine and releasing S-adenosyl-L-homocysteine (SAH). This reaction is catalyzed by a conserved catalytic motif in the DNMT domain.
Cofactor Binding and Catalysis
In simple terms: SAM acts as the methyl donor, and the enzyme uses it to perform the modification.
SAM binds to the catalytic domain of DNMTs, positioning the methyl group for transfer. The reaction proceeds via a nucleophilic attack on the methyl group, facilitated by conserved cysteine and glutamate residues.
Regulation of Activity
In simple terms: The enzyme's activity is controlled by various factors, including other proteins and modifications.
DNA-methyltransferase activity is regulated at multiple levels, including protein-protein interactions (e.g., with DNMT3L for de novo methylation), post-translational modifications, and availability of SAM. Dysregulation of these regulatory mechanisms can lead to aberrant DNA methylation patterns in disease [1,5].
Assays for Measuring Activity
In simple terms: Scientists use various techniques to detect how much methyltransferase activity is present.
Activity assays include radioactive labeling, fluorescence-based methods (e.g., FRET), electrochemical sensors, and CRISPR-Cas12a-based amplification. These methods enable sensitive detection of DNMT activity for research and clinical applications [1,2,3,4,6,7,8].
Key Genes Involved in GO:0009008 DNA-methyltransferase activity
The following genes encode DNA methyltransferases and related proteins that are central to DNA-methyltransferase activity and its regulation.
| Gene | Major Role | Research Relevance |
|---|---|---|
| DNMT1 | Maintenance methyltransferase; copies methylation patterns during DNA replication | Knockout leads to global hypomethylation and embryonic lethality; target for cancer therapy [1,5] |
| DNMT3A | De novo methyltransferase; establishes new methylation patterns | Mutations found in acute myeloid leukemia and other cancers; knockout models show developmental defects |
| DNMT3B | De novo methyltransferase; involved in early development and repetitive element silencing | Mutations cause immunodeficiency-centromeric instability-facial anomalies (ICF) syndrome; knockout is embryonic lethal |
| DNMT3L | Regulatory factor; stimulates DNMT3A/3B activity but lacks catalytic activity | Knockout causes imprinting defects and infertility; important for studying regulation |
| UHRF1 | Recruits DNMT1 to hemimethylated DNA during replication | Knockout results in hypomethylation and genomic instability; target in cancer |
| MBD proteins | Bind methylated DNA and recruit repressive complexes | Used to study methylation-dependent gene silencing |
| TET1 | Catalyzes oxidation of 5-methylcytosine to 5-hydroxymethylcytosine | Counteracts DNA methylation; knockout affects development and cancer |
| TET2 | Involved in DNA demethylation | Mutations in leukemia and other cancers; knockout models show hematopoietic defects |
| TET3 | Oxidizes 5-methylcytosine in zygotes and embryonic stem cells | Knockout affects zygotic reprogramming |
| DNMT1 (isoform) | Somatic isoform; maintenance of methylation | Overexpression linked to cancer progression |
| DNMT3A (isoform) | De novo methylation in germ cells and embryos | Point mutations used to study catalytic vs. non-catalytic functions |
| DNMT3B (isoform) | De novo methylation in early development | Knock-in models for ICF syndrome mutations |
| SAM synthetase (MAT2A) | Produces SAM, the methyl donor | Knockout reduces methylation; target for metabolic studies |
| SAHH (AHCY) | Hydrolyzes SAH to prevent feedback inhibition | Knockout affects methylation potential; linked to hypermethioninemia |
| MBD4 | Glycosylase that removes methylated cytosine deamination products | Knockout increases mutation rate at CpG sites |
| GADD45A | Involved in active DNA demethylation | Overexpression can induce demethylation; knockout affects gene activation |
| IDH1/2 | Mutants produce 2-hydroxyglutarate, inhibiting TET enzymes | Mutations in gliomas and leukemia; knock-in models for oncometabolite studies |
| DNMT3A R882 | Common mutant in AML with dominant-negative effect | Point mutation knock-in models for leukemia research |
How Is DNA-methyltransferase activity Regulated?
DNA-methyltransferase activity is tightly regulated at multiple levels. The availability of the methyl donor SAM, which is synthesized by methionine adenosyltransferase (MAT2A) and recycled via SAH hydrolase (AHCY), directly influences activity. Protein-protein interactions, such as DNMT3L stimulating DNMT3A/3B, modulate de novo methylation. Post-translational modifications (e.g., phosphorylation, ubiquitination) and subcellular localization also control DNMT function. Additionally, TET enzymes counteract methylation by oxidizing 5-methylcytosine, and their activity is regulated by metabolites such as 2-hydroxyglutarate in cancer. Dysregulation of these pathways leads to aberrant methylation patterns in diseases.
DNA-methyltransferase activity and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| DNMT3A | Acute myeloid leukemia (AML) | Knockout and point mutation (R882H) knock-in in hematopoietic stem cells |
| DNMT3B | ICF syndrome | Knockout and knock-in of patient mutations in cell lines |
| DNMT1 | Cancer, neurodegeneration | Knockout in cancer cell lines; overexpression in neurons |
| TET2 | Leukemia, clonal hematopoiesis | Knockout and point mutation knock-in in mouse models |
| IDH1/2 | Glioma, AML | Knock-in of IDH mutations to study oncometabolite effects |
Cancer
Aberrant DNA methylation is a hallmark of cancer. Hypermethylation of tumor suppressor gene promoters leads to their silencing, while global hypomethylation contributes to genomic instability and oncogene activation. Mutations in DNMT3A are frequent in acute myeloid leukemia (AML) and are associated with poor prognosis. DNMT inhibitors such as azacitidine and decitabine are used in myelodysplastic syndromes and AML, highlighting the clinical relevance of DNA-methyltransferase activity.
Imprinting Disorders
Defects in DNA methylation at imprinting control regions cause disorders such as Beckwith-Wiedemann syndrome and Silver-Russell syndrome. Mutations in DNMT3L or DNMT3B can disrupt imprinting, leading to developmental abnormalities.
Neurological and Neurodegenerative Diseases
Altered DNA methylation patterns have been observed in Alzheimer's disease, Parkinson's disease, and schizophrenia. Environmental factors can influence methylation, contributing to disease risk.
Immunodeficiency-Centromeric Instability-Facial Anomalies (ICF) Syndrome
Mutations in DNMT3B cause ICF syndrome, characterized by immunodeficiency, centromeric instability, and facial anomalies. This rare disorder underscores the importance of de novo methylation in development and immune function.
From DNA-methyltransferase activity-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| What is the effect of DNMT1 loss on global methylation? | DNMT1 knockout cell lines (e.g., HCT116) |
| How does DNMT3A R882H mutation contribute to leukemia? | Point mutation knock-in in hematopoietic cells |
| Can we rescue ICF syndrome phenotypes by restoring DNMT3B function? | Knock-in of wild-type DNMT3B in patient-derived cells |
| What is the role of DNMT3L in imprinting? | DNMT3L knockout mouse models |
| How does overexpression of DNMT3B affect tumorigenesis? | Overexpression of DNMT3B in cancer cell lines |
| Can we track DNMT1 localization in live cells? | Tagged knock-in of DNMT1 with fluorescent protein |
How to Study the DNA-methyltransferase activity Process
| Method | What It Measures | Typical Application |
|---|---|---|
| Radioactive methylation assay | Incorporation of radioactive methyl groups into DNA | Quantification of DNMT activity in vitro |
| FRET-based assay | Real-time methyl transfer using fluorescent probes | High-throughput screening of DNMT inhibitors |
| Electrochemical biosensor | Current changes upon methylation | Point-of-care detection of DNMT activity |
| Nanomaterial-based biosensor | Optical or electrical signals from methylated DNA | Sensitive detection in clinical samples |
| CRISPR-Cas12a assay | Fluorescence from Cas12a trans-cleavage | Ultrasensitive detection of DNMT activity |
| AIE-based assay | Aggregation-induced emission from DNA polymerization | Simple and rapid activity measurement |
| Dual-amplification fluorescence | Signal amplification via two strategies | Ultrasensitive detection of DNMT activity |
| MBD-based assay | Binding of methyl-binding domain proteins to methylated DNA | Detection of methylation levels |
Radioactive and Fluorescence-Based Assays
Traditional assays use radioactive SAM to measure methyl transfer, while fluorescence-based methods (e.g., FRET) offer real-time, non-radioactive detection of DNA-methyltransferase activity [1,2].
Electrochemical and Nanomaterial-Based Biosensors
Electrochemical sensors and nanomaterial-based biosensors provide sensitive, label-free detection of DNMT activity, often using methyl-binding domain proteins or customized detectors [4,7].
CRISPR-Cas12a Amplification Assays
Recent methods combine strand displacement amplification with CRISPR-Cas12a for ultrasensitive detection of DNMT activity, enabling robust and multiplexed analysis.
Template-Free DNA Polymerization and AIE
Template-free DNA polymerization coupled with aggregation-induced emission (AIE) allows simple and sensitive measurement of DNMT activity.
How CRISPR Can Be Used to Study GO:0009008 DNA-methyltransferase activity
Knockout
CRISPR knockout of DNMT genes (e.g., DNMT1, DNMT3A, DNMT3B) enables researchers to study loss-of-function phenotypes, such as global hypomethylation, developmental defects, and tumor suppression. Knockout cell lines are valuable for drug sensitivity testing and epigenetic studies [1,5].
Point Mutation
Introducing specific point mutations (e.g., DNMT3A R882H) via CRISPR allows modeling of disease-associated mutations and dissecting catalytic versus non-catalytic functions. These models are crucial for understanding leukemogenesis and testing targeted therapies.
Knock-in
Knock-in of reporter tags (e.g., fluorescent proteins) or patient-specific mutations into DNMT genes facilitates live-cell imaging, localization studies, and functional rescue experiments. Knock-in models help validate drug targets and study imprinting disorders [1,5].
Overexpression
CRISPR activation (CRISPRa) or transgenic overexpression of DNMTs allows investigation of gain-of-function effects, such as hypermethylation and oncogenesis. Overexpression models are useful for screening epigenetic drugs and studying dosage effects.
How EDITGENE Supports DNA-methyltransferase activity Research
Researchers studying DNA-methyltransferase activity-related genes often need to determine whether a candidate gene is causally involved in epigenetic regulation, disease progression, or drug response. Precise genetic models are essential to link gene function to phenotype and to validate therapeutic targets.
Contact EDITGENE today to design your custom CRISPR model for DNA-methyltransferase activity research.
Related Products
| Product name | Cat.No. | Species | Gene ID | |
|---|---|---|---|---|
| DNMT3B Knockout HEK293 Cell Line | EDJ-KQ2278 | Human | 1789 | Details Get a Quote |
| MGMT Knockout HEK293 Cell Line | EDJ-KQ3115 | Human | 4255 | Details Get a Quote |
| DNMT3B Knockout A-549 Cell Line | EDJ-KQ22624 | Human | 1789 | Details Get a Quote |
| DNMT3B Knockout HCT 116 Cell Line | EDJ-KQ22625 | Human | 1789 | Details Get a Quote |
| DNMT3B Knockout HeLa Cell Line | EDJ-KQ22626 | Human | 1789 | Details Get a Quote |
| MGMT Knockout A-549 Cell Line | EDJ-KQ24460 | Human | 4255 | Details Get a Quote |
| MGMT Knockout HCT 116 Cell Line | EDJ-KQ24461 | Human | 4255 | Details Get a Quote |
| MGMT Knockout HeLa Cell Line | EDJ-KQ24462 | Human | 4255 | Details Get a Quote |
| DNMT1 Knockout HAP1 Cell Line | EDJ-KQ78106 | Human | 1786 | Details Get a Quote |
| DNMT1 Knockout HEK293T Cell Line | EDJ-KQ78134 | Human | 1786 | Details Get a Quote |
| DNMT1 Knockout HCT 116 Cell Line | EDJ-KQ78135 | Human | 1786 | Details Get a Quote |
Displaying Records 1 To 11 Of 11 Records
Frequently Asked Questions About DNA-methyltransferase activity
What is DNA-methyltransferase activity?
DNA-methyltransferase activity (GO:0009008) is the catalysis of methyl group transfer to a DNA molecule, typically forming 5-methylcytosine, a key epigenetic modification.
What genes are involved in DNA-methyltransferase activity?
Key genes include DNMT1, DNMT3A, DNMT3B, and DNMT3L, which encode enzymes that establish and maintain DNA methylation patterns [1,5].
How is DNA-methyltransferase activity measured?
It can be measured using radioactive assays, fluorescence-based methods (e.g., FRET), electrochemical biosensors, and CRISPR-Cas12a-based amplification [1,2,3,4,6,7,8].
Why is DNA-methyltransferase activity important in cancer?
Aberrant DNA methylation, driven by dysregulated DNMT activity, leads to silencing of tumor suppressors and genomic instability, contributing to cancer development and progression.
What diseases are associated with DNA-methyltransferase mutations?
Mutations in DNMT3A are linked to acute myeloid leukemia, DNMT3B to ICF syndrome, and aberrant methylation to imprinting disorders and neurological diseases.
What is the role of SAM in DNA-methyltransferase activity?
S-adenosyl-L-methionine (SAM) serves as the methyl donor, providing the methyl group that is transferred to DNA by DNMTs.
How can CRISPR be used to study DNA-methyltransferase activity?
CRISPR can create knockout, point mutation, knock-in, and overexpression models of DNMT genes to dissect their functions and roles in disease [1,5].
What are the challenges in assaying DNA-methyltransferase activity?
Challenges include sensitivity, specificity, and the need for real-time detection; advances in biosensors and amplification methods address these issues [1,3,4,8].
Can DNA-methyltransferase activity be inhibited therapeutically?
Yes, DNMT inhibitors such as azacitidine and decitabine are used in myelodysplastic syndromes and leukemia, and new inhibitors are under development.
What is the difference between DNMT1 and DNMT3A/3B?
DNMT1 primarily maintains methylation during replication, while DNMT3A and DNMT3B establish de novo methylation patterns during development [1,5].
Conclusion
DNA-methyltransferase activity (GO:0009008) is a fundamental epigenetic mechanism that regulates gene expression, development, and genome stability. Its dysregulation is implicated in cancer, imprinting disorders, and neurological diseases, making it a key target for research and therapy. Advances in assay technologies and CRISPR-based models continue to deepen our understanding of this activity and its roles in health and disease.
References
- 1. Poh WJ et al.. 2016. DNA Methyltransferase Activity Assays: Advances and Challenges.. Theranostics 6(3):369-91 PMID: 26909112
- 2. Long Y et al.. 2021. FRET-Based Method for Direct, Real-Time Measurement of DNA Methyltransferase Activity.. Bioconjug Chem 32(1):192-198 PMID: 33306345
- 3. Wen Q et al.. 2022. Ultrasensitive detection of DNA methyltransferase activity: a novel dual-amplification fluorescence technique.. Analyst 147(22):4980-4985 PMID: 36197295
- 4. Ma F et al.. 2020. Nanomaterial-based biosensors for DNA methyltransferase assay.. J Mater Chem B 8(16):3488-3501 PMID: 32095792
- 5. Laird PW. 2005. Cancer epigenetics.. Hum Mol Genet 14 Spec No 1:R65-76 PMID: 15809275
- 6. Niu S et al.. 2020. Detection of DNA methyltransferase activity using template-free DNA polymerization amplification based on aggregation-induced emission.. Anal Biochem 590:113532 PMID: 31821806
- 7. Lu L et al.. 2019. Electrochemical determination of the activity of DNA methyltransferase based on the methyl binding domain protein and a customized modular detector.. Mikrochim Acta 186(4):229 PMID: 30848391
- 8. Yu F et al.. 2025. Bifunctional probe propelling multipath strand displacement amplification tandem CRISPR/Cas12a for ultrasensitive and robust assay of DNA methyltransferase activity.. Anal Chim Acta 1337:343540 PMID: 39800499
